Nabriva Therapeutics plc
Hedge Funds Holdings
Last updated:
Nabriva Therapeutics plc‘s stocks are currently a part of 23 hedge funds’ portfolios, which represents 6.95% of the total amount of its stocks outstanding. This makes up a total of 3.01M shares of Nabriva Therapeutics plc. Compared to the previous quarter, the number fell by -25.13% or -1.01M shares fewer. As for the holding position changes, 17.39% (4) of current hedge fund investors increased the number of shares held, 26.09% (6) of current holders sold a part of the shares held, and 47.83% (11) closed the holdings completely. 6 hedge funds are new holders of Nabriva Therapeutics plc stock in Q1 2022, it is 26.09% of total holders.
Hedge funds holding Nabriva Therapeutics (Q2 2017 – Q1 2022)
| Q2 2017 | 24 |
|---|---|
| Q3 2017 | 41 |
| Q4 2017 | 44 |
| Q1 2018 | 45 |
| Q2 2018 | 41 |
| Q3 2018 | 44 |
| Q4 2018 | 46 |
| Q1 2019 | 39 |
| Q2 2019 | 38 |
| Q3 2019 | 43 |
| Q4 2019 | 47 |
| Q1 2020 | 46 |
| Q2 2020 | 49 |
| Q3 2020 | 45 |
| Q4 2020 | 29 |
| Q1 2021 | 28 |
| Q2 2021 | 25 |
| Q3 2021 | 26 |
| Q4 2021 | 28 |
| Q1 2022 | 23 |
Hedge funds changes in Nabriva Therapeutics positions (Q2 2017 – Q1 2022)
| Q2 2017 | 20 | 1 | 1 | 21 | -19 |
|---|---|---|---|---|---|
| Q3 2017 | 24 | 11 | 4 | 7 | -5 |
| Q4 2017 | 20 | 8 | 5 | 15 | -4 |
| Q1 2018 | 7 | 9 | 17 | 6 | 6 |
| Q2 2018 | 7 | 15 | 11 | 11 | -3 |
| Q3 2018 | 13 | 18 | 8 | 10 | -5 |
| Q4 2018 | 12 | 7 | 16 | 10 | 1 |
| Q1 2019 | 5 | 13 | 9 | 12 | 0 |
| Q2 2019 | 7 | 13 | 7 | 8 | 3 |
| Q3 2019 | 12 | 16 | 5 | 7 | 3 |
| Q4 2019 | 12 | 12 | 9 | 8 | 6 |
| Q1 2020 | 12 | 9 | 13 | 11 | 1 |
| Q2 2020 | 12 | 12 | 6 | 9 | 10 |
| Q3 2020 | 8 | 11 | 7 | 12 | 7 |
| Q4 2020 | 27 | 1 | 1 | 43 | -43 |
| Q1 2021 | 6 | 7 | 6 | 7 | 2 |
| Q2 2021 | 3 | 6 | 7 | 6 | 3 |
| Q3 2021 | 3 | 6 | 8 | 2 | 7 |
| Q4 2021 | 7 | 4 | 7 | 5 | 5 |
| Q1 2022 | 6 | 4 | 6 | 11 | -4 |
Hedge funds changes in Nabriva Therapeutics stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 0 | 0 |
|---|---|---|
| Q3 2017 | 0 | 0 |
| Q4 2017 | 62,000 | 13,000 |
| Q1 2018 | 115,000 | 114,000 |
| Q2 2018 | 492,000 | 121,000 |
| Q3 2018 | 32,000 | 109,000 |
| Q4 2018 | 1,000 | 18,000 |
| Q1 2019 | 453,000 | 9,000 |
| Q2 2019 | 272,000 | 212,000 |
| Q3 2019 | 321,000 | 128,000 |
| Q4 2019 | 103,000 | 82,000 |
| Q1 2020 | 216,000 | 26,000 |
| Q2 2020 | 1,037,000 | 1,000 |
| Q3 2020 | 1,039,000 | 99,000 |
| Q4 2020 | 2,192,000 | 279,000 |
| Q1 2021 | 1,409,000 | 475,000 |
| Q2 2021 | 1,539,000 | 394,000 |
| Q3 2021 | 847,000 | 251,000 |
| Q4 2021 | 275,000 | 150,000 |
| Q1 2022 | 41,000 | 6,000 |
Top 50 hedge fund holders of Nabriva Therapeutics plc (NASDAQ:NBRV)
| Hedge fund | Value | Shares owned | Portfolio share |
|---|---|---|---|
| VALUES FIRST ADVISORS, INC. | 54K | 25.89K | 0.039% |
| RENAISSANCE TECHNOLOGIES LLC Jim Simons | 43K | 20.56K | 0.000% |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 35K | 17.02K | 0.003% |
| MORGAN STANLEY | 9K | 4.39K | 0.000% |
| ADVISOR GROUP HOLDINGS, INC. | 4K | 2K | 0.000% |
| IFP ADVISORS, INC | 1K | 700 | 0.000% |
| UBS GROUP AG | 1K | 381 | 0.000% |
| MORGAN STANLEY | 0 | 0 | 0.000% |
| ADVISOR GROUP HOLDINGS, INC. | 0 | 0 | 0.000% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0 | 0 | 0.000% |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 0 | 0 | 0.000% |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0.000% |
| ABG INNOVATION CAPITAL PARTNERS III GP LTD | 0 | 0 | 0.000% |
| FMR LLC | 0 | 0 | 0.000% |
| UBS GROUP AG | 0 | 0 | 0.000% |
| VIRTU FINANCIAL LLC | 0 | 0 | 0.000% |
| WEDBUSH SECURITIES INC | 0 | 0 | 0.000% |
| VALUES FIRST ADVISORS, INC. | 0 | 0 | 0.000% |
| CCG WEALTH MANAGEMENT, LLC | 0 | 0 | 0.000% |
| AISLING CAPITAL MANAGEMENT LP | 0 | 0 | 0.000% |
| JANE STREET GROUP, LLC | 0 | 0 | 0.000% |
| RENAISSANCE TECHNOLOGIES LLC Jim Simons | 0 | 0 | 0.000% |
| RUNNING POINT CAPITAL ADVISORS, LLC | 0 | 0 | 0.000% |
| CITADEL ADVISORS LLC Ken Griffin | 0 | 0 | 0.000% |